Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.41 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320872 | 0.78 | CDK4 (0.39) | GAAJAK1 | |
| SCHEMBL1320653 | 0.69 | RET (0.47) | ALDH1A1KDM4EHPGDRIOK2SMN1; SMN2 | |
| SCHEMBL1320400 | 0.68 | RET (0.44) | KDM4ERIOK2NPC1KMT2ALMNA | |
| SCHEMBL1319610 | 0.68 | USP7 (0.49) | ALDH1A1KDM4EHPGDKMT2ACSNK1D | |
| SCHEMBL1320178 | 0.68 | MAPK14 (0.44) | GAACACNA1HRIOK2SMN1; SMN2LMNA | |
| SCHEMBL1320937 | 0.68 | USP7 (0.46) | GAAALDH1A1CACNA1HNPC1RAB9A | |
| SCHEMBL1322686 | 0.68 | TP53 (0.46) | GAACACNA1HKMT2A | |
| SCHEMBL1319684 | 0.68 | TP53 (0.46) | GAACACNA1HKMT2A | |
| SCHEMBL1320171 | 0.67 | NPC1 (0.49) | GAAALDH1A1KDM4EHPGDNPC1 | |
| SCHEMBL1319242 | 0.67 | USP7 (0.56) | GAAALDH1A1KDM4EHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018208-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | ICAGEN INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8431608-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2178373-B1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2536718-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8058274-B2 | Heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2011102964-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2178373-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009026254-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | KCNK10, KCNK9, KCNJ2 | GAA 1408/4885JAK1 2004/4885ALDH1A1 2020/4885 |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | GAA 1268/4885JAK1 2202/4885ALDH1A1 2150/4885 |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | GAA 1268/4885JAK1 2202/4885ALDH1A1 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.